Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Tran C, et al. Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9. Science. 2009. PMID: 19359544 Free PMC article. Clinical Trial.
ARN-509: a novel antiandrogen for prostate cancer treatment.
Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. Clegg NJ, et al. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. Cancer Res. 2012. PMID: 22266222 Free PMC article.
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET.
Beattie BJ, Smith-Jones PM, Jhanwar YS, Schöder H, Schmidtlein CR, Morris MJ, Zanzonico P, Squire O, Meirelles GS, Finn R, Namavari M, Cai S, Scher HI, Larson SM, Humm JL. Beattie BJ, et al. J Nucl Med. 2010 Feb;51(2):183-92. doi: 10.2967/jnumed.109.066159. Epub 2010 Jan 15. J Nucl Med. 2010. PMID: 20080885 Free PMC article.
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.
Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, Smith-Jones P, Schwartz L, Kelly WK, Slovin S, Solit D, Halpern J, Delacruz A, Curley T, Finn R, O'donoghue JA, Livingston P, Larson S, Scher HI. Morris MJ, et al. Clin Cancer Res. 2005 Oct 15;11(20):7454-61. doi: 10.1158/1078-0432.CCR-05-0826. Clin Cancer Res. 2005. PMID: 16243819 Clinical Trial.
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM. Pandit-Taskar N, et al. Among authors: smith jones pm. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2093-105. doi: 10.1007/s00259-014-2830-7. Epub 2014 Aug 21. Eur J Nucl Med Mol Imaging. 2014. PMID: 25143071 Free PMC article. Clinical Trial.
Radioimmunotherapy of prostate cancer.
Smith-Jones PM. Smith-Jones PM. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):297-304. Q J Nucl Med Mol Imaging. 2004. PMID: 15640793 Free article. Review.
82 results